1. Home
  2. MLCI vs ATOS Comparison

MLCI vs ATOS Comparison

Compare MLCI & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MLCI

Mount Logan Capital Inc.

N/A

Current Price

$5.76

Market Cap

69.6M

Sector

Finance

ML Signal

N/A

Logo Atossa Therapeutics Inc.

ATOS

Atossa Therapeutics Inc.

HOLD

Current Price

$5.18

Market Cap

36.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MLCI
ATOS
Founded
N/A
2009
Country
United States
United States
Employees
21
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
69.6M
36.2M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
MLCI
ATOS
Price
$5.76
$5.18
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$31.67
AVG Volume (30 Days)
60.3K
76.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
2.12%
N/A
EPS Growth
N/A
16.67
EPS
N/A
N/A
Revenue
N/A
$1,758.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.86
$0.53
52 Week High
$8.68
$7.56

Technical Indicators

Market Signals
Indicator
MLCI
ATOS
Relative Strength Index (RSI) 48.94 69.77
Support Level N/A $0.68
Resistance Level $8.54 $7.56
Average True Range (ATR) 0.29 0.36
MACD 0.16 -0.04
Stochastic Oscillator 86.50 92.24

Price Performance

Historical Comparison
MLCI
ATOS

About MLCI Mount Logan Capital Inc.

Mount Logan Capital Inc operates as emerging asset management and investment firm focused on investing in public and private debt securities in the North American market. The Company's reporting segments include asset management and insurance. The asset management segment reflects the Company's historical operations through its subsidiaries, including ML Management, and the insurance segment represents Ability's operations. The Company through its subsidiaries, earns management and incentive fees and servicing fees for providing investment management, monitoring and other services to investment vehicles and advisers. The insurance business is operated by Ability. Ability's insurance business consists of premium revenue from long term care insurance policies.

About ATOS Atossa Therapeutics Inc.

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Share on Social Networks: